HUP0102504A2 - Nikotinreceptor agonista pozitív modulátorának alkalmazása csökkent nikotintranszmisszióval társult állapotok kezelésére szolgáló gyógyászati készítmények előállítására - Google Patents
Nikotinreceptor agonista pozitív modulátorának alkalmazása csökkent nikotintranszmisszióval társult állapotok kezelésére szolgáló gyógyászati készítmények előállításáraInfo
- Publication number
- HUP0102504A2 HUP0102504A2 HU0102504A HUP0102504A HUP0102504A2 HU P0102504 A2 HUP0102504 A2 HU P0102504A2 HU 0102504 A HU0102504 A HU 0102504A HU P0102504 A HUP0102504 A HU P0102504A HU P0102504 A2 HUP0102504 A2 HU P0102504A2
- Authority
- HU
- Hungary
- Prior art keywords
- nicotinic receptor
- receptor agonist
- positive modulator
- compound
- positive
- Prior art date
Links
- 229940123925 Nicotinic receptor agonist Drugs 0.000 title abstract 10
- 239000000181 nicotinic agonist Substances 0.000 title abstract 10
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 230000005540 biological transmission Effects 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 229960002715 nicotine Drugs 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 210000004027 cell Anatomy 0.000 abstract 3
- 230000000694 effects Effects 0.000 abstract 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 abstract 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 abstract 2
- LMIQERWZRIFWNZ-UHFFFAOYSA-N 5-hydroxyindole Chemical group OC1=CC=C2NC=CC2=C1 LMIQERWZRIFWNZ-UHFFFAOYSA-N 0.000 abstract 1
- 241000269370 Xenopus <genus> Species 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000000897 modulatory effect Effects 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 210000000287 oocyte Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Addiction (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
A találmány tárgya olyan gyógyszerkészítmény, amely egy nikotin-receptor agonista olyan pozitív modulátorát tartalmazzagyógyszerészetileg elfogadható hordozóval és egy nikotin-receptoragonistával együtt, amely pozitív modulátor képes a nikotin-receptoragonista hatásosságának növelésére. Az említett pozitív modulátor az5-hidroxi-indol, az említett nikotin-receptor agonista pedig egy a7-nikotin-receptor agonista. A találmány tárgya továbbá egy nikotin-receptor agonista pozitív modulátorának azonosítására szolgálóeljárás, amelyben egy sejt, így Xenopus oocyta, HEK-293 sejt vagy egysejttenyésztett neuron felületén kifejeztetnek egy nikotin-receptort,ezt érintkezésbe hozzák egy nikotin-receptor agonistának ismertvegyülettel és egy pozitív modulátor hatásra vizsgálandó vegyülettel,és meghatározzák, hogy a vegyület mutat-e pozitív moduláló hatást.Ugyancsak a találmány tárgyát képezi egy nikotin-receptor agonistavegyület azonosítására szolgáló eljárás, amelyben a sejt felületénkifejeztetett nikotin-receptort egy pozitív modulátor jelenlétébenérintkezésbe hozzák az agonista aktivitásra vizsgálandó vegyülettel,és meghatározzák, hogy az mutat-e nikotin-receptor agonistaaktivitást. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/071,826 US6277870B1 (en) | 1998-05-04 | 1998-05-04 | Use |
PCT/SE1999/000700 WO1999056745A1 (en) | 1998-05-04 | 1999-04-28 | New use |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0102504A2 true HUP0102504A2 (hu) | 2001-11-28 |
HUP0102504A3 HUP0102504A3 (en) | 2002-12-28 |
Family
ID=22103848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0102504A HUP0102504A3 (en) | 1998-05-04 | 1999-04-28 | Use of a positive modulator of a nicotinic receptor agonist in the manufacture of a medicament for treatment of a condition associated with reduced nicotine transmission |
Country Status (27)
Country | Link |
---|---|
US (2) | US6277870B1 (hu) |
EP (1) | EP1079828B1 (hu) |
JP (1) | JP2002513757A (hu) |
KR (1) | KR20010043266A (hu) |
CN (2) | CN1299279A (hu) |
AR (1) | AR016217A1 (hu) |
AT (1) | ATE249827T1 (hu) |
AU (1) | AU770849B2 (hu) |
BR (1) | BR9910180A (hu) |
CA (1) | CA2331070A1 (hu) |
DE (1) | DE69911400T2 (hu) |
EE (1) | EE200000640A (hu) |
HK (1) | HK1034205A1 (hu) |
HU (1) | HUP0102504A3 (hu) |
ID (1) | ID27289A (hu) |
IL (1) | IL139145A0 (hu) |
IS (1) | IS5699A (hu) |
MY (1) | MY116027A (hu) |
NO (1) | NO20005503L (hu) |
PL (1) | PL343923A1 (hu) |
RU (1) | RU2225203C2 (hu) |
SK (1) | SK284608B6 (hu) |
TR (1) | TR200003244T2 (hu) |
TW (1) | TW542718B (hu) |
UA (1) | UA65617C2 (hu) |
WO (1) | WO1999056745A1 (hu) |
ZA (1) | ZA200006133B (hu) |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
JP2005510482A (ja) * | 2001-10-16 | 2005-04-21 | アストラゼネカ・アクチエボラーグ | 線維筋痛症候群の治療方法 |
CN100371714C (zh) * | 2001-12-14 | 2008-02-27 | 塔加西普特公司 | 治疗中枢神经系统病症的方法和组合物 |
US7091357B2 (en) * | 2001-12-26 | 2006-08-15 | University Of Kentucky Research Foundation | Chain-modified pyridino-N substituted nicotine compounds for use in the treatment of CNS pathologies |
DE10164139A1 (de) | 2001-12-27 | 2003-07-10 | Bayer Ag | 2-Heteroarylcarbonsäureamide |
US7781396B2 (en) * | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US20040052928A1 (en) * | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US20030162770A1 (en) | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20030236287A1 (en) * | 2002-05-03 | 2003-12-25 | Piotrowski David W. | Positive allosteric modulators of the nicotinic acetylcholine receptor |
US7358057B2 (en) | 2002-05-09 | 2008-04-15 | Memory Pharmaceuticals Corporation | QM-7 and QT-6 cells transfected with mutant cell surface expressed channel receptors and assays using the transfected cells |
US7244745B2 (en) | 2002-08-30 | 2007-07-17 | Memory Pharmaceuticals Corp. | Heterocyclic compounds, methods for the preparation thereof, and uses thereof |
JP4890762B2 (ja) | 2002-09-25 | 2012-03-07 | メモリー・ファーマシューティカルズ・コーポレイション | インダゾール、ベンゾチアゾール、及びベンゾイソチアゾール、並びにそれらの調製及び使用 |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
EP1583713B1 (en) | 2003-01-07 | 2009-03-25 | Ramot at Tel Aviv University Ltd. | Peptide nanostructures encapsulating a foreign material and method of manufacturing same |
JP4917889B2 (ja) | 2003-09-25 | 2012-04-18 | テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル.ピー. | アミロイド関連疾患を処置するための組成物及びその使用方法 |
WO2005031362A2 (en) * | 2003-10-02 | 2005-04-07 | Ramot At Tel Aviv University Ltd. | Novel antibacterial agents and methods of identifying and utilizing same |
DE602004010299T2 (de) | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
CN103724343A (zh) | 2004-03-25 | 2014-04-16 | 记忆药物公司 | 吲唑、苯并噻唑、苯并异噻唑、苯并异噁唑及其制备和用途 |
WO2006001894A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
BRPI0510212A (pt) | 2004-05-07 | 2007-10-16 | Memory Pharm Corp | 1h-indazóis, benzotiazóis, 1,2 - benzoisoxazóis, 1,2-benzoisotiazóis, e cromonas e a preparação e usos dos mesmos |
US20090156471A1 (en) * | 2004-07-15 | 2009-06-18 | Ramot At Tel Aviv University Ltd. | Use of anti-amyloid agents for treating and typing pathogen infections |
EP1781310B1 (en) * | 2004-08-02 | 2015-10-14 | Ramot at Tel Aviv University Ltd. | Articles of peptide nanostructures and method of forming the same |
ATE539745T1 (de) | 2004-08-19 | 2012-01-15 | Univ Tel Aviv Future Tech Dev | Zusammensetzungen zur behandlung von amyloid- assoziierten erkrankungen |
WO2006027780A2 (en) | 2004-09-08 | 2006-03-16 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures containing end-capping modified peptides and methods of generating and using the same |
MX2007007328A (es) | 2004-12-22 | 2007-07-25 | Memory Pharm Corp | Ligandos del receptor alfa-7 nicotinico y preparacion y sus usos. |
PL1883451T3 (pl) * | 2005-04-13 | 2011-05-31 | Neuraxon Inc | Podstawione związki indolowe mające aktywność hamowania NOS |
US8106066B2 (en) | 2005-09-23 | 2012-01-31 | Memory Pharmaceuticals Corporation | Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof |
WO2007043048A2 (en) * | 2005-10-11 | 2007-04-19 | Ramot At Tel Aviv University Ltd. | Self-assembled fmoc-ff hydrogels |
US7879212B2 (en) * | 2005-11-03 | 2011-02-01 | Ramot At Tel-Aviv University Ltd. | Peptide nanostructure-coated electrodes |
US20070134169A1 (en) * | 2005-12-11 | 2007-06-14 | Rabinoff Michael D | Methods for smoking cessation or alcohol cessation or other addiction cessation |
ZA200809659B (en) * | 2006-04-13 | 2010-03-31 | Neuraxon Inc | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity |
US8314119B2 (en) | 2006-11-06 | 2012-11-20 | Abbvie Inc. | Azaadamantane derivatives and methods of use |
MX356032B (es) * | 2007-11-16 | 2018-04-11 | Neuraxon Inc | Compuestos indola y métodos para tratar el dolor visceral. |
CA2705422A1 (en) * | 2007-11-16 | 2009-05-22 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Methods for treating visceral pain |
PE20110711A1 (es) | 2008-11-19 | 2011-10-11 | Envivo Pharmaceuticals Inc | Tratamiento de trastornos cognitivos con (r)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmaceuticamente aceptables de la misma |
MX2011011972A (es) * | 2009-05-11 | 2011-12-08 | Envivo Pharmaceuticals Inc | Tratamiento de trastornos cognitivos con determinados receptores de acido nicotinico alfa-7 en combinacion con inhibidores de acetilcolinesterasa. |
DK2571874T3 (en) | 2010-05-17 | 2016-05-17 | Forum Pharmaceuticals Inc | A crystalline form of (R) -7-chloro-N- (quinuclidin-3-yl) benzo [b] thiophene-2-carboxamide hydrochloride monohydrate |
MX2013003344A (es) | 2010-09-23 | 2013-06-28 | Abbvie Inc | Monohidrato de un derivado de azaadamantano. |
CA2872005A1 (en) | 2012-05-08 | 2013-11-14 | Forum Pharmaceuticals, Inc. | Methods of maintaining, treating or improving cognitive function |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2649009B1 (fr) * | 1989-07-03 | 1991-10-11 | Oreal | Procede de teinture des fibres keratiniques a base de monohydroxyindole et de 5,6-dihydroxyindole et composition mise en oeuvre |
US5272155A (en) * | 1991-12-05 | 1993-12-21 | Abbott Laboratories | (+)-2-methylpiperidine as modulator of cholinergic systems |
HUT74949A (en) * | 1993-09-10 | 1997-03-28 | Cytomed | Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists |
EP0777671B1 (en) * | 1994-08-24 | 2000-04-26 | Astra Aktiebolag | Spiro-azabicyclic compounds useful in therapy |
SE9600683D0 (sv) * | 1996-02-23 | 1996-02-23 | Astra Ab | Azabicyclic esters of carbamic acids useful in therapy |
AR013184A1 (es) * | 1997-07-18 | 2000-12-13 | Astrazeneca Ab | Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis |
US6277870B1 (en) | 1998-05-04 | 2001-08-21 | Astra Ab | Use |
-
1998
- 1998-05-04 US US09/071,826 patent/US6277870B1/en not_active Expired - Fee Related
-
1999
- 1999-04-21 TW TW088106373A patent/TW542718B/zh not_active IP Right Cessation
- 1999-04-22 AR ARP990101861A patent/AR016217A1/es unknown
- 1999-04-28 UA UA2000126907A patent/UA65617C2/uk unknown
- 1999-04-28 IL IL13914599A patent/IL139145A0/xx unknown
- 1999-04-28 EP EP99948542A patent/EP1079828B1/en not_active Expired - Lifetime
- 1999-04-28 DE DE69911400T patent/DE69911400T2/de not_active Expired - Fee Related
- 1999-04-28 KR KR1020007012221A patent/KR20010043266A/ko not_active Application Discontinuation
- 1999-04-28 TR TR2000/03244T patent/TR200003244T2/xx unknown
- 1999-04-28 WO PCT/SE1999/000700 patent/WO1999056745A1/en not_active Application Discontinuation
- 1999-04-28 EE EEP200000640A patent/EE200000640A/xx unknown
- 1999-04-28 CA CA002331070A patent/CA2331070A1/en not_active Abandoned
- 1999-04-28 SK SK1570-2000A patent/SK284608B6/sk unknown
- 1999-04-28 CN CN99805760A patent/CN1299279A/zh active Pending
- 1999-04-28 CN CNA2004100880671A patent/CN1637149A/zh active Pending
- 1999-04-28 AU AU43023/99A patent/AU770849B2/en not_active Ceased
- 1999-04-28 HU HU0102504A patent/HUP0102504A3/hu unknown
- 1999-04-28 BR BR9910180-7A patent/BR9910180A/pt not_active IP Right Cessation
- 1999-04-28 JP JP2000546771A patent/JP2002513757A/ja active Pending
- 1999-04-28 AT AT99948542T patent/ATE249827T1/de not_active IP Right Cessation
- 1999-04-28 PL PL99343923A patent/PL343923A1/xx not_active Application Discontinuation
- 1999-04-28 RU RU2000130209/15A patent/RU2225203C2/ru not_active IP Right Cessation
- 1999-05-04 MY MYPI99001750A patent/MY116027A/en unknown
- 1999-05-28 ID IDW20002260A patent/ID27289A/id unknown
-
2000
- 2000-10-30 ZA ZA200006133A patent/ZA200006133B/en unknown
- 2000-11-01 NO NO20005503A patent/NO20005503L/no not_active Application Discontinuation
- 2000-11-01 IS IS5699A patent/IS5699A/is unknown
-
2001
- 2001-03-20 US US09/812,269 patent/US6861443B2/en not_active Expired - Fee Related
- 2001-07-17 HK HK01105008A patent/HK1034205A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0102504A2 (hu) | Nikotinreceptor agonista pozitív modulátorának alkalmazása csökkent nikotintranszmisszióval társult állapotok kezelésére szolgáló gyógyászati készítmények előállítására | |
AU1718400A (en) | Method for treating pain | |
AU6286698A (en) | Methods of using exendin and glp-1, and agonists and antagonists thereof, to affect the central nervous system | |
AU2003263067A1 (en) | Improved diffuse optical tomography system and method of use | |
JP2002513757A5 (hu) | ||
BR9915744A (pt) | Derivados 4-arilquinolin-2-ona 3-substituìdos como moduladores do canal de potássio | |
AU2002305797A1 (en) | Slc22as as modifiers of the p53 pathway and methods of use | |
YU38801A (sh) | Azabicikloalkani kao modulatori ccr5 | |
NZ504258A (en) | Exendin 3 and 4 agonist compounds for the treatment of diabetes | |
HK1074573A1 (en) | Tetrahydroquinoline analogues as muscarinic agonists | |
NO994706D0 (no) | Farmasöytisk blanding for oraladministrering av et N-piperidino-3-pyrazolkarboksyamidderivat, samt salter og solvater derav | |
AU4078997A (en) | Cholinesterase inhibitors for treatment of parkinson's disease | |
HUP0101546A2 (hu) | Opioid antagonistát és NMDA-receptor komplex modulátort tartalmazó gyógyászati készítmény alkohol- és drogfüggőség kezelésére | |
NO20004419L (no) | Ny anvendelse | |
Gao et al. | Epigenetic regulations through DNA methylation and hydroxymethylation: clues for early pregnancy in decidualization | |
MXPA00006306A (es) | Compuestos del canal de ion del cerebro o corazon, regulados por nucleotidos ciclicos y usos de los mismos. | |
AU2219999A (en) | Methods for preparing and using immortalized human neuroendocrine cells | |
AU2002242858A1 (en) | Patch-clamping and its use in analysing subcellular features | |
NO960826L (no) | Anvendelse av enzymer fra krill i forstoffer | |
DE60322228D1 (de) | Schnell zerfallende tablette | |
AU4178497A (en) | HTm4, methods of treatment and assays, agonists and antagonists | |
MXPA04010915A (es) | Base y procedimiento de conocimiento de recursos humanos dinamicos. | |
ZA988009B (en) | Methods of administering an ampa receptor antagonist to treat dyskinesias associated with dopamine agonist therapy. | |
AU4937499A (en) | Use of succinic acid or salts thereof and method of treating insulin resistance | |
AU1101301A (en) | 2,2-difluoro 15-hydroxyeicosatetraenoic acid analogs and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD9A | Lapse of provisional protection due to non-payment of fees |